Total Payments
$597.77
2021 Payments
$14.43
Companies
16
Transactions
38
Medicare Patients
3,649
Medicare Billing
$763,065
Payment Breakdown by Category
Food & Beverage$597.77 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $597.77 | 38 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $139.17 | 10 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $101.23 | 7 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $68.62 | 4 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $55.63 | 3 | $0 (2020) |
| Janssen Biotech, Inc. | $41.02 | 2 | $0 (2019) |
| Taiho Oncology, Inc. | $31.84 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $27.74 | 2 | $0 (2019) |
| Allergan Inc. | $21.15 | 1 | $0 (2017) |
| Daiichi Sankyo Inc. | $18.57 | 1 | $0 (2018) |
| Novo Nordisk Inc | $18.53 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $14.43 | 1 | E.R. Squibb & Sons, L.L.C. ($14.43) |
| 2020 | $58.33 | 4 | AstraZeneca Pharmaceuticals LP ($17.63) |
| 2019 | $171.87 | 11 | E.R. Squibb & Sons, L.L.C. ($44.56) |
| 2018 | $206.61 | 13 | PFIZER INC. ($73.39) |
| 2017 | $146.53 | 9 | PFIZER INC. ($41.42) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.43 | General |
| Category: Oncology | ||||||
| 02/21/2020 | Tactile Systems Technology Inc | FLEXITOUCH (Device), ACTITOUCH, ENTRE | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 02/19/2020 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 02/15/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.78 | General |
| Category: Oncology | ||||||
| 01/17/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Oncology | ||||||
| 12/13/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Food and Beverage | In-kind items and services | $11.56 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2019 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.42 | General |
| Category: Cardiovascular | ||||||
| 10/04/2019 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: Oncology | ||||||
| 09/20/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Oncology | ||||||
| 09/16/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $11.51 | General |
| Category: Oncology | ||||||
| 05/10/2019 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.24 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Oncology | ||||||
| 03/15/2019 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $19.63 | General |
| Category: Cardiovascular | ||||||
| 03/09/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2019 | Lexicon Pharmaceuticals, Inc. | Xermelo (Drug) | Food and Beverage | In-kind items and services | $11.51 | General |
| Category: Carcinoid Syndrome Diarrhea | ||||||
| 12/01/2018 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Anemia | ||||||
| 10/16/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/21/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Oncology | ||||||
| 09/14/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 09/07/2018 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $18.53 | General |
| 08/29/2018 | PFIZER INC. | XALKORI (Drug), IBRANCE | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2018 | Novartis Pharmaceuticals Corporation | TAFINLAR (Drug), MEKINIST | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: ONCOLOGY | ||||||
| 08/24/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 07/13/2018 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 763 | 2,277 | $272,058 | $148,160 |
| 2022 | 6 | 940 | 3,438 | $398,469 | $199,203 |
| 2021 | 6 | 914 | 3,778 | $435,894 | $219,333 |
| 2020 | 8 | 1,032 | 3,232 | $377,101 | $196,369 |
Total Patients
3,649
Total Services
12,725
Medicare Billing
$763,065
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 315 | 1,759 | $188,072 | $105,843 | 56.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 174 | 203 | $42,705 | $19,754 | 46.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 167 | 197 | $24,802 | $12,092 | 48.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 107 | 118 | $16,479 | $10,473 | 63.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 398 | 2,786 | $297,879 | $151,308 | 50.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 209 | 254 | $53,434 | $25,608 | 47.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 198 | 232 | $29,209 | $12,638 | 43.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 92 | 95 | $13,267 | $7,334 | 55.3% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2022 | 22 | 50 | $3,000 | $1,484 | 49.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 21 | 21 | $1,680 | $831.33 | 49.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 422 | 3,171 | $339,043 | $173,040 | 51.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 189 | 257 | $54,065 | $26,312 | 48.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 200 | 239 | $30,090 | $13,235 | 44.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 69 | 70 | $9,776 | $5,364 | 54.9% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 22 | 23 | $1,840 | $904.42 | 49.2% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2021 | 12 | 18 | $1,080 | $476.84 | 44.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 468 | 2,522 | $269,652 | $143,625 | 53.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 204 | 261 | $54,907 | $27,706 | 50.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 187 | 231 | $29,083 | $13,134 | 45.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 46 | 47 | $6,564 | $3,791 | 57.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 18 | $4,729 | $2,880 | 60.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 42 | 51 | $5,687 | $2,505 | 44.1% |
| G0179 | Physician re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial imp | Office | 2020 | 49 | 84 | $5,040 | $2,021 | 40.1% |
| G0180 | Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implem | Office | 2020 | 18 | 18 | $1,440 | $707.42 | 49.1% |
About Dr. Cesar Vivanco, MD
Dr. Cesar Vivanco, MD is a Specialist healthcare provider based in El Paso, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1992843163.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cesar Vivanco, MD has received a total of $597.77 in payments from pharmaceutical and medical device companies, with $14.43 received in 2021. These payments were reported across 38 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($597.77).
As a Medicare-enrolled provider, Vivanco has provided services to 3,649 Medicare beneficiaries, totaling 12,725 services with total Medicare billing of $763,065. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Hematology & Oncology
- Location El Paso, TX
- Active Since 02/01/2007
- Last Updated 03/06/2017
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1992843163
Products in Payments
- CHANTIX (Drug) $68.75
- OPDIVO (Biological) $68.18
- ELIQUIS (Drug) $59.68
- KISQALI (Drug) $52.35
- DARZALEX (Biological) $41.02
- TAGRISSO (Drug) $38.00
- Lonsurf (Drug) $31.84
- XALKORI (Drug) $29.00
- NAMZARIC (Drug) $21.15
- INJECTAFER (Drug) $18.57
- CALQUENCE (Drug) $17.63
- TAFINLAR (Drug) $16.27
- ZERBAXA (Drug) $16.18
- XARELTO (Drug) $14.84
- VIAGRA (Drug) $14.79
- FLEXITOUCH (Device) $13.80
- Kcentra (Biological) $12.16
- LENVIMA (Drug) $11.56
- Xermelo (Drug) $11.51
- Avastin (Biological) $11.16
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in El Paso
Dr. Mohammed Alnajjar, Md, MD
Specialist — Payments: $753,687
Specialist $753,687
Dr. Louis Alpern, M.d, M.D
Specialist — Payments: $354,223
Specialist $354,223
Jeanette Tan, M.d, M.D
Specialist — Payments: $189,193
Specialist $189,193
Dr. Sadri Sozer, M.d, M.D
Specialist — Payments: $181,669
Specialist $181,669
Dr. Keith Johnson, M.d. P.a, M.D. P.A
Specialist — Payments: $81,732
Specialist $81,732
Dr. Ines Sanchez-Rivera, M.d, M.D
Specialist — Payments: $63,950
Specialist $63,950